Finn Willingham PhD

Head of ATTC Network Coordination, Cell and Gene Therapy Catapult

Finn Willingham

Finn has over 25 years’ experience in business development, marketing and project management roles in the biotechnology and healthcare sectors. In her current role, Finn coordinates the Advanced Therapy Treatment Centre (ATTC) Network, a major Innovate UK-funded programme established to help accelerate clinical testing and adoption of Advanced Therapy Medicinal Products (ATMPs) by the UK’s National Health Services. This includes co-chairing ATMP Engage, a UK ATMP public involvement and engagement working group. Finn’s interest in ATMPs originated whilst Director of Business Development of a CDMO, working with an array of start-up and established biotech companies developing these innovative products.

Advanced Therapies: : Navigating Challenges and Fostering Collaboration for Patient Access

Cell and gene therapies are changing the way we think about and treat rare diseases. We’ll ask “is there adequate service provision, staffing and infrastructure in place to deliver each and every gene therapy safely, effectively and efficiently?”

My three wishes for the future of rare disease are: Equitable access to advanced therapies, supported by timely diagnosis and delivery of treatments in easy-to-reach centres with appropriate capacity and capability.